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NOD-like receptors (NLRs) are increasingly implicated in regulating pathogen-sensing pathways. In this issue
of Immunity, Zhang et al. (2014) describe a role for NLRC3 in regulating STING and the inflammatory response
to cytosolic DNA.Intracellular sensing of nucleic acids is
integral for the initiation of antimicrobial
responses. The protein stimulator of inter-
feron genes (STING) has emerged as a
nonredundant molecule in the DNA-
sensing pathway that drives both proin-
flammatory cytokine and type I interferon
production (Barber, 2014). Cells lacking
STING fail to mount a robust immune
response to diverse variants of cytosolic
DNA, including viral DNA, plasmid DNA,
and DNA released from apoptotic or
necrotic cells. Furthermore, mice lacking
STING fail to control the DNA virus herpes
simplex virus 1 (HSV-1) because of a
deficiency in type I interferon generation
(Barber, 2014).
STING directly senses various types of
cyclic dinucleotides delivered by bacteria.
In addition, cytosolic double-stranded
DNA activates cyclic GMP-AMP synthase
(cGAS) to produce a unique isomer of
cyclic GMP-AMP (cGAMP) from GTP
and ATP. The nucleotidyltransferase
cGAS thereby generates an endogenous
ligand to activate STING (Barber, 2014).
Given that STING plays a central role
in DNA recognition and the sensing of
intracellular bacteria, it is not surprising
that its activity must be tightly controlled.
Indeed, previous work has shown that
STING is regulated by both ubiquitination
and phosphorylation, suggesting that it is
finely tuned by multiple feedback mecha-
nisms (Barber, 2014).
In this issue of Immunity, Zhang et al.
(2014) demonstrate a role for a NOD-like
receptor (NLR) in regulating the activity
of STING. NLRs are best known for their
ability to form large signaling complexes,
termed inflammasomes, which activate
capase-1, leading to cleavage and
release of the interleukin-1b (IL-1b) family
of cytokines (Latz et al., 2013). In addi-tion to these proinflammatory functions,
increasing evidence indicates that certain
NLRs can also regulate diverse inflam-
matory pathways. The NF-kB signaling
pathway, for example, is tuned down by
NLRs including NLRP2, NLRC3, NLRP6,
and NLRP12 (Lupfer and Kanneganti,
2013).
Zhang et al. (2014) demonstrate that
deficiency of NLRC3 results in complete
protection from an otherwise lethal infec-
tion of HSV-1. Further in vitro studies
established that NLRC3 also controls
STING activation by cytosolic dsDNA. In
addition, inhibition of cellular responses
by NLRC3 extended to the bacterial
derived cyclic dinucleotides, suggesting
that NLRC3 may control STING directly
rather than a DNA sensor such as cGAS.
The inhibitory role of NLRC3 is intriguing
given that it is also implicated in limiting
NF-kB activation after LPS stimulation
by binding TRAF6, resulting in TRAF6
degradation (Schneider et al., 2012).
These dual roles performed by NLRC3 in
response to diverse immune stimuli
suggest that NLRC3 behaves as a
watchdog to prevent an overshooting
onset of immune responses. TLR activa-
tion also results in decreased transcrip-
tion of NLRC3, essentially releasing the
brake on NF-kB activation mediated by
MyD88-dependent receptors (Schneider
et al., 2012). This suggests that NLRC3
is part of a finely tuned feedback system
that regulates the strength and timing of
inflammatory signaling. It would thus be
interesting to investigate whether pre-
priming WT macrophages with TLR ago-
nists would accelerate STING responses
to cytosolic dsDNA (Figure 1).
Further biochemical investigation of
NLRC3-mediated inhibition of STING re-
vealed that the two proteins interactImmunity 4directly via the nucleotide binding domain
(NBD) of NLRC3. Notably, expression of a
construct containing the NBD and LRR
domains inhibited the interaction with
STING. It is therefore possible that the
LRR domain regulates the NBD-STING
interaction. It remains unclear, however,
whether this direct interaction is required
for NLRC3-mediated inhibition of STING
signaling. The NBD of NLRC3 also medi-
ates its interaction with TRAF6, which
occurs through a TRAF binding motif
(Ser-Leu-Gln-Glu) in the NBD (Schneider
et al., 2012). Whether STING and TRAF6
share this interaction site on NLRC3 or
whether both TRAF6 and STING could
potentially interact with the NBD of
NLRC3 through distinct sites remains to
be investigated.
The authors also sought to ascertain
how NLRC3 mediates inhibition of STING
by investigating the effect of NLRC3 on
the interaction between STING and
TBK1. In the absence of NLRC3, the
kinetics of the STING-TBK1 interaction
was accelerated, indicating that NLRC3
may delay the interaction between the
two but not entirely prevent it. Further-
more, NLRC3 inhibited the translocation
of STING from the ER to perinuclear
puncta, a feature required for full
TBK1 activation (Barber, 2014). Whether
NLRC3 restricts the STING-TBK1 interac-
tion by preventing STING translocation to
the perinuclear puncta or by interfering
with the interaction site between STING
and TBK1 has not been addressed.
An overarching question from these
studies is how a single NLR can perform
different roles. This study demonstrates
that NLRC3 can regulate two seem-
ingly unconnected signaling pathways,
TRAF6 signaling and STING signal-
ing. Other NLRs, such as NLRP6 and0, March 20, 2014 ª2014 Elsevier Inc. 305
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Figure 1. NLRC3 Controls STING Activation and Type I Interferon Secretion
STING is triggered by cyclic dinucleotides released from bacteria or generated by cGAS upon recognition
of cytosolic dsDNA. Zhang et al. (2014) demonstrate that NLRC3 binds to STING, sequestering it at the ER
and preventing it from interacting with TBK1. After viral infection, TLR9 and STING activate NF-kB, which
lowers NLRC3 expression. Hence, it is possible that these pathways commence a positive-feedback loop,
resulting in increased type I interferon production and secretion through enhanced STING activity.
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leading to the activation of caspase-1-
dependent cytokines, and in addition
can suppress NF-kB-, ERK-, and MAP-
kinase-dependent immune cell activation
(Anand et al., 2012; Zaki et al., 2014). It
is conceivable that such NLRs are consti-
tutively expressed, and in the absence of
certain immune stimuli act to repress the
signaling pathways leading to proinflam-
matory factors. However, upon recogni-
tion of a specific stimulus, some of the
NLRs will form an inflammasome to pro-
mote cleavage and release of IL-1b
(Lupfer and Kanneganti, 2013). Therefore,
the immune downregulatory function of
these NLRs may be controlled by their
transcription, whereas the proinflamma-
tory activities, which are typically regu-
lated by additional means, will occur
only in response to a specific stimulus.
However, in the work by Zhang et al.
(2014), it was shown that the LRR region306 Immunity 40, March 20, 2014 ª2014 Elseappears to reduce binding of the NBD
domain to STING. This would suggest
the exciting possibility that an unidenti-
fied activation signal or scaffold may be
required to expose the NBD domain and
thus allow its regulatory function to occur.
Thus far it is unclear whether and when
the negative regulatory activity of NLRs
is required to promote homeostatic
conditions and prevent immune-driven
pathology. It is intriguing that both
NLRP6- and NLRC3-deficient mice, for
example, appear to have a survival advan-
tage during pathogenic infection (Anand
et al., 2012; Zhang et al., 2014). For
NLRP6, this protection seems to occur
at the cost of reduced control of the gut
microbiome and increased susceptibility
for inflammatory pathologies upon dietary
challenge (Elinav et al., 2011). NLRC3
provides minor protection against LPS-
induced septic shock (Schneider et al.,
2012). However, it remains to be deter-vier Inc.mined whether the lack of NLRC3
has further, as-of-yet-undefined liabilities.
Further investigation must be made into
how these negatively regulating proteins
act under normal conditions, because
currently it is not sufficiently clear how
expression of these proteins is advanta-
geous to the immune system.
NLRC3 joins the growing list of NLRs
involved in negative regulation of immune
responses, though it is the first impli-
cated in control of the cytosolic dsDNA
response. The STING pathway can con-
tribute to inflammatory pathologies and
the development of autoimmune diseases
under conditions of increased appear-
ance or oxidative modifications of endog-
enousDNA (Ahn et al., 2012; Gehrke et al.,
2013). Hence, it would be interesting to
test whether NLRC3 functions to sup-
press inflammation and autoimmune
responses in models of systemic lupus
erythematosis. Moreover, it is possible
that inactivating mutations in NLRC3
might be associated with autoimmune
disorders involving detection of self-DNA.REFERENCES
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